Expression of phosphatase and tensin homologue in imprint smears of endometrial carcinoma

Kosmas, Konstantinos; Mitropoulou, Georgia; Provatas, Ioannis; Stamoulas, Marios; Marouga, Anna

doi:10.1111/cyt.12612

Cited by 2 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All the 11 proteins have been studied by immunohistochemistry in primary tissue specimens. Notably, MKI67 and PTEN were also validated in tissue samples from imprint smears [51][52][53], as well as CDH1, which was analyzed in uterine aspirates using mass spectrometry-based approaches [54]. MUC16 and WFDC2 have been extensively studied in serum samples by antibody-based techniques such as ELISA or chemiluminescence techniques [50,[55][56][57] and L1CAM was also validated in serum but just in one study [58].…”

Section: Prognostic Protein Biomarkers In Ecmentioning

confidence: 99%

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Rubia

Martínez‐García

Dittmar

et al. 2020

JCM

View full text Add to dashboard Cite

Endometrial cancer (EC) is the sixth most common cancer in women worldwide and its mortality is directly associated with the presence of poor prognostic factors driving tumor recurrence. Stratification systems are based on few molecular, and mostly clinical and pathological parameters, but these systems remain inaccurate. Therefore, identifying prognostic EC biomarkers is crucial for improving risk assessment pre- and postoperatively and to guide treatment decisions. This systematic review gathers all protein biomarkers associated with clinical prognostic factors of EC, recurrence and survival. Relevant studies were identified by searching the PubMed database from 1991 to February 2020. A total number of 398 studies matched our criteria, which compiled 255 proteins associated with the prognosis of EC. MUC16, ESR1, PGR, TP53, WFDC2, MKI67, ERBB2, L1CAM, CDH1, PTEN and MMR proteins are the most validated biomarkers. On the basis of our meta-analysis ESR1, TP53 and WFDC2 showed potential usefulness for predicting overall survival in EC. Limitations of the published studies in terms of appropriate study design, lack of high-throughput measurements, and statistical deficiencies are highlighted, and new approaches and perspectives for the identification and validation of clinically valuable EC prognostic biomarkers are discussed.

show abstract

Section: Prognostic Protein Biomarkers In Ecmentioning

confidence: 99%

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Rubia

Martínez‐García

Dittmar

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…In vitro data have demonstrated that the PI3K-Akt signaling pathway contributes to the carcinogenesis of EC (61). A study of patients with EC observed that PTEN expression is negatively associated with myometrial invasion depth, indicating that PTEN may play an important role of in the development of EC and is potentially a prognostic indicator of EC (62). It has been reported that metformin inhibits Akt expression and stimulates PTEN and IP3 expression via inhibition of the PI3K-Akt signaling pathway (63).…”

Section: Metformin Directly Inhibits the Development Of Ecmentioning

confidence: 99%

Therapeutic effect of metformin in the treatment of endometrial cancer (Review)

Gao

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

The present review aims at reviewing the role of metformin in the treatment of endometrial cancer (EC). According to the literature, excessive estrogen levels and insulin resistance are established risk factors of EC. As a traditional insulin sensitizer and newly discovered anticancer agent, metformin directly and indirectly inhibits the development of EC. The direct mechanisms of metformin include inhibition of the LKB1-AMP-activated protein kinase-mTOR, PI3K-Akt and insulin-like growth factor 1-related signaling pathways, which reduces the proliferation and promotes the apoptosis of EC cells. In the indirect mechanism, metformin increases the insulin sensitivity of body tissues and decreases circulating insulin levels. Decreased levels of insulin increase the blood levels of sex hormone binding globulin, which leads to reductions in circulating estrogen and androgens. The aforementioned findings suggest that metformin serves an important role in the treatment of EC. Increased understanding of the mechanism of metformin in EC may provide novel insights into the treatment of this malignancy.

show abstract

Expression of phosphatase and tensin homologue in imprint smears of endometrial carcinoma

Cited by 2 publications

References 46 publications

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Therapeutic effect of metformin in the treatment of endometrial cancer (Review)

Contact Info

Product

Resources

About